Mr Sam Scott

  • Research Assistant (Virology)

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022
Number of items: 12.

2024

Roberts, T. et al. (2024) Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer Journal, 14, 22. (doi: 10.1038/s41408-023-00940-5) (PMID:38272915) (PMCID:PMC10810811)

2023

Willett, B. J. et al. (2023) Omicron BA.2.86 cross-neutralising activity in community sera from the UK. Lancet, 402(10417), pp. 2075-2076. (doi: 10.1016/s0140-6736(23)02397-8) (PMID:37952549)

Tyson, G. B. et al. (2023) Increase in SARS-CoV-2 seroprevalence in UK domestic felids despite weak immunogenicity of post-Omicron variants. Viruses, 15(8), 1661. (doi: 10.3390/v15081661) (PMID:37632004) (PMCID:PMC10458763)

Dowell, A. C. et al. (2023) Immunological imprinting of humoral immunity to SARS-CoV-2 in children. Nature Communications, 14, 3845. (doi: 10.1038/s41467-023-39575-2) (PMID:37386081) (PMCID:PMC10310754)

Martin, C. A. et al. (2023) Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis. EClinicalMedicine, 58, 101926. (doi: 10.1016/j.eclinm.2023.101926) (PMID:37034357) (PMCID:PMC10071048)

Manali, M. et al. (2023) SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity. Journal of Infectious Diseases, 227(1), pp. 40-49. (doi: 10.1093/infdis/jiac332) (PMID:35920058) (PMCID:PMC9384671)

Liew, F. et al. (2023) SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine, 87, 104402. (doi: 10.1016/j.ebiom.2022.104402) (PMID:36543718) (PMCID:PMC9762734)

2022

Willett, B. J. et al. (2022) Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 7, 1709. (doi: 10.1038/s41564-022-01241-6) (PMID:36114232) (PMCID:PMC9483304)

Parry, H. et al. (2022) Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people. Cell Reports Medicine, 3(9), 100739. (doi: 10.1016/j.xcrm.2022.100739) (PMID:36075216) (PMCID:PMC9404227)

Willett, B. J. et al. (2022) SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 7(8), pp. 1161-1179. (doi: 10.1038/s41564-022-01143-7) (PMID:35798890) (PMCID:PMC9352574)

Parry, H. et al. (2022) COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia. Cancer Cell, 40(6), pp. 584-586. (doi: 10.1016/j.ccell.2022.05.001) (PMID:35588735) (PMCID:PMC9072807)

Dowell, A. C. et al. (2022) mRNA or ChAd0x1 COVID-19 vaccination of adolescents induces robust antibody and cellular responses with continued recognition of omicron following mRNA-1273. Frontiers in Immunology, 13, 882515. (doi: 10.3389/fimmu.2022.882515) (PMID:35720281) (PMCID:PMC9201026)

This list was generated on Sat Apr 26 10:38:35 2025 BST.
Jump to: Articles
Number of items: 12.

Articles

Roberts, T. et al. (2024) Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer Journal, 14, 22. (doi: 10.1038/s41408-023-00940-5) (PMID:38272915) (PMCID:PMC10810811)

Willett, B. J. et al. (2023) Omicron BA.2.86 cross-neutralising activity in community sera from the UK. Lancet, 402(10417), pp. 2075-2076. (doi: 10.1016/s0140-6736(23)02397-8) (PMID:37952549)

Tyson, G. B. et al. (2023) Increase in SARS-CoV-2 seroprevalence in UK domestic felids despite weak immunogenicity of post-Omicron variants. Viruses, 15(8), 1661. (doi: 10.3390/v15081661) (PMID:37632004) (PMCID:PMC10458763)

Dowell, A. C. et al. (2023) Immunological imprinting of humoral immunity to SARS-CoV-2 in children. Nature Communications, 14, 3845. (doi: 10.1038/s41467-023-39575-2) (PMID:37386081) (PMCID:PMC10310754)

Martin, C. A. et al. (2023) Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis. EClinicalMedicine, 58, 101926. (doi: 10.1016/j.eclinm.2023.101926) (PMID:37034357) (PMCID:PMC10071048)

Manali, M. et al. (2023) SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity. Journal of Infectious Diseases, 227(1), pp. 40-49. (doi: 10.1093/infdis/jiac332) (PMID:35920058) (PMCID:PMC9384671)

Liew, F. et al. (2023) SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine, 87, 104402. (doi: 10.1016/j.ebiom.2022.104402) (PMID:36543718) (PMCID:PMC9762734)

Willett, B. J. et al. (2022) Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 7, 1709. (doi: 10.1038/s41564-022-01241-6) (PMID:36114232) (PMCID:PMC9483304)

Parry, H. et al. (2022) Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people. Cell Reports Medicine, 3(9), 100739. (doi: 10.1016/j.xcrm.2022.100739) (PMID:36075216) (PMCID:PMC9404227)

Willett, B. J. et al. (2022) SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 7(8), pp. 1161-1179. (doi: 10.1038/s41564-022-01143-7) (PMID:35798890) (PMCID:PMC9352574)

Parry, H. et al. (2022) COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia. Cancer Cell, 40(6), pp. 584-586. (doi: 10.1016/j.ccell.2022.05.001) (PMID:35588735) (PMCID:PMC9072807)

Dowell, A. C. et al. (2022) mRNA or ChAd0x1 COVID-19 vaccination of adolescents induces robust antibody and cellular responses with continued recognition of omicron following mRNA-1273. Frontiers in Immunology, 13, 882515. (doi: 10.3389/fimmu.2022.882515) (PMID:35720281) (PMCID:PMC9201026)

This list was generated on Sat Apr 26 10:38:35 2025 BST.